An interventional study of Probiotic and Placebo in COVID-19 Respiratory Infection, sponsored by Nordic Biotic Sp. z o.o.. Completed at 3 sites in Ukraine. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-22.
Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in COVID-19 with a site in Ukraine — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Ukraine.
Among the 45 studies in COVID-19 with a site in Ukraine, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 23 that started in 2021, is one of 2 with no phase, and was the 28th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →1 of the 45 studies in COVID-19 with a site in Ukraine is open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Ukraine, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 26 · Phase 4 3
First in 2020; this study’s year is marked. 23 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 285 across the 39 interventional studies, 1,003 across the 6 observational. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 45 have an industry lead sponsor. The 10 most frequent:
Nordic Biotic Sp. z o.o. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Nordic Biotic Sp. z o.o. has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies in COVID-19 with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
There is evidence that some types of probiotics play a role in alleviation of symptoms of acute respiratory tract infections and bursting immune response to respiratory and enteric viruses. Available data serves a rationale for the study exploring a role of nutritional support with probiotics in adult outpatients with COVID-19. Hypothesis of the study is that a proposed mixture of lactobacilli and bifidobacteria facilitate faster recovery from COVID-19 and enhance specific immune response to SARS-CoV-2 antigens.
One hundred adults with confirmed (PCR or antigen test) symptomatic COVID-19 lasting upto 5 days will be screened for the study. When the subject meets enrollment criteria, he/she will be randomized to take an investigational product (probiotic, test dietary supplement, TDS), a mixture of lactobacilli and bifidobacteria or placebo 1 time a day before breakfast for 28 days after enrollment. During observation, the patient will keep Respiratory Illness Diary. Blood serum will be collected at baseline, day 0-5 (Nurse Visit 1), after 28-35 days (Nurse visit 2), and 6 months (Nurse visit 3) for evaluation of anti-SARS-CoV-2 antibodies to nucleocapsid and spike antigents. In 3 months, investigator/family physician will collect Post-COVID-19 Questionnaire
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Risk for the complicated course of COVID-19 due to:
1.1. Hypertension; 1.2. Diabetes mellitus; 1.3. conditions; 1.4. Chronic pathology of the respiratory system ; 1.5. Chronic pathology of the cardiovascular system ; 1.6. Malignant tumor ; 1.7. Systemic inflammatory connective tissue disease ; 1.8. Cerebrovascular disease ; 1.9. Chronic hepatitis. Hepatic cirrhosis; 1.10. Inflammatory bowel diseases ; 1.11. Chronic kidney disease ;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for 28 days
Dietary Supplement: Probiotic
Maltodextrine administered once a day for 28 days
Dietary Supplement: Placebo
Probiotic will be taken 1 time a day before breakfast for 28 days.
Placebo will be taken 1 time a day before breakfast for 28 days.
Global symptom score
Clinical score of Coronavirus disease-19; minimal score 0 (healthy), maximal score 36 (worst disease)
Time frame: 10 days
8 - point ordinal severity scale of coronavirus disease-19
World Health Organization scale; score 0 - healthy, score 8 - death
Time frame: 28 days
Time to recovery
Day when patient symptom score is 0
Time frame: 28 days
Percent of completely recovered patients
Patients with symptom score is 0
Time frame: 28 days
Hospitalization rate
Percent hospitalized due to COVID-19
Time frame: 28 days
Anti-SARS-CoV-2 antibodies IgG response
Antibody titer to NCP and spike antigen
Time frame: Days 0-5, day 28-35, month 6th
Plan to share: No — Not applicable as not decided yet
Ran from Dec 2021 to primary completion in Dec 2022, 12 months.
Of 138 industry-sponsored interventional studies with no phase under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 12 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Nordic Biotic Sp. z o.o.